Ruo Yu Chen

Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.

GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA.

Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA.

Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China.

Part of Robert Half, Inc., Protiviti LLC is a business consulting firm that provides IT consulting, risk and compliance, digital transformation, and internal audit services. The company is based in Tokyo, Japan. Protiviti also offers a platform for alumni to connect, reminisce, and stay in touch, as well as to introduce, employ, and mentor fellow alumni.